Full-Time

Clinical Oncology Specialist

Posted on 12/20/2024

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Biotechnology
Healthcare

Compensation Overview

$185k - $225kAnnually

Senior

Buffalo, NY, USA

Territory includes Buffalo, NY.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Sales
Requirements
  • Bachelor’s degree and at least 5 years of Oncology experience OR associate degree and 7 years of Oncology experience.
  • Knowledge of local oncology market.
  • Knowledge of oncology molecular diagnostics and personalized medicine.
Responsibilities
  • Learn Natera products, services, processes, policies, key internal teams, as well as competitor’s products, services, policies and practices, and payer/reimbursement landscape in the territory to be effective in the COS role.
  • Identify Key Opinion Leaders (KOLs), hospitals, clinics and physicians that are appropriate for Natera products & services in the territory and gain their trust and business.
  • Calls on oncologists and other medical personnel to provide product information for the sale of Natera’s Oncology diagnostics.
  • Capitalize on selling opportunities and/or to influence physician, key opinion leaders, hospitals and clinics.
  • Responsible for the sale of the company’s oncology diagnostics products within an assigned territory or geographic region.
  • Monitor, document and report on existing business as well as challenges and new opportunities. Escalate issues not resolved timely or to the satisfaction of the clients.
  • Conduct business in an ethical & transparent fashion.
  • Perform other duties as assigned.

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology, cell-free DNA (cfDNA) testing, analyzes DNA fragments in the blood to detect minimal traces of cancer and monitor organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services, directly to healthcare providers and patients. The company's goal is to improve patient care through precise genetic insights that support informed medical decisions.

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Growth & Insights
Headcount

6 month growth

9%

1 year growth

25%

2 year growth

66%
Simplify Jobs

Simplify's Take

What believers are saying

  • Signatera test detects cancer recurrence earlier than traditional imaging.
  • Prospera Heart's DQS improves accuracy in transplant rejection risk assessment.
  • Natera's extensive cfDNA experience supports innovation across multiple health sectors.

What critics are saying

  • Hindenburg report alleges deceptive sales practices, risking legal and reputational issues.
  • New testing features may face slow adoption by healthcare providers.
  • Fetal RhD test demand may decline post-RhIg shortage, affecting sales.

What makes Natera unique

  • Natera's cfDNA technology is pivotal in prenatal and cancer diagnostics.
  • The Donor Quantity Score (DQS) enhances Prospera Heart's transplant rejection detection.
  • Natera's fetal RhD test addresses RhIg shortages, offering unique prenatal solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks